Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350911 | 1.00 | CYP2C9 (0.35) | CYP2C9FUCA1 | |
| SCHEMBL10325969 | 0.81 | FUCA1 (0.32) | FUCA1 | |
| SCHEMBL15256198 | 0.81 | FUCA1 (0.32) | FUCA1 | |
| SCHEMBL10325972 | 0.81 | CYP2C9 (0.33) | CYP2C9FUCA1 | |
| SCHEMBL15256195 | 0.81 | FUCA1 (0.32) | FUCA1 | |
| SCHEMBL12441374 | 0.77 | FUCA1 (0.39) | CYP2C9FUCA1 | |
| SCHEMBL12441372 | 0.77 | FUCA1 (0.39) | FUCA1 | |
| SCHEMBL19009052 | 0.74 | — | — | |
| SCHEMBL15359127 | 0.74 | — | — | |
| SCHEMBL13973921 | 0.74 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-9220683-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-12-29 | — | — | US | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CYP2C9 4757/4885FUCA1 2254/4885 |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CYP2C9 4757/4885FUCA1 2254/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CYP2C9 4708/4885FUCA1 2297/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | CYP2C9 4708/4885FUCA1 2297/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | CYP2C9 4048/4885FUCA1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.